Dergiler / Haydarpaşa Numune Medical Journal / 2022 / Cilt: 62 - Sayı: 1

The Success Rate of Interferon-Based Treatments in Chronic Viral Hepatitis C Patients and Factors Affecting Treatment Success

Sayfa
48–53
Yayın Tarihi
2022-10-19
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Discussion and Conclusion: In our study, the response rate of patients to interferon-based treatment was 42.8%, while young age, female gender, and absence of organomegaly were determined as factors that increased this rate, and according to multiple analyses, it was determined that combined treatment alone was effective on SVR independently.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Introduction: To examine the treatment success and the factors affecting the treatment success in patients with chronic viral hepatitis C.
📊
Temel Bulgular & Veri:Results: 418 patients were included in the study.
💡
Sonuç & Katkı:Discussion and Conclusion: In our study, the response rate of patients to interferon-based treatment was 42.8%, while young age, female gender, and absence of organomegaly were determined as factors that increased this rate, and according to multiple analyses, it was determined that combined treatment alone was effective on SVR independently.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Introduction: To examine the treatment success and the factors affecting the treatment success in patients with chronic viral hepatitis C. Methods: This retrospective study was conducted by scanning the files of patients with chronic viral hepatitis C, who were followed in Infectious Diseases and Gastroenterology outpatient clinics. Demographic and clinical characteristics (presence of hepatomegaly or splenomegaly, comorbidity treatment protocols, and side effects) were examined. Results: 418 patients were included in the study. The mean age of the patients was 48.4 (min: 27-max:76) years. 40.4% (n=169) of the patients were male. Fifty patients had hepatomegaly and 45 had splenomegaly. While 79.9% of the patients had no comorbid disease, 13.4% had diabetes, 5.3% had thyroid dysfunction, and 1.4% had both. Hepatocellular carcinoma was observed in 4 patients, cirrhosis was observed in 29 patients, and side effects were observed in 33 patients. Four patients received ribavirin, 32 patients received classical interferon, 13 patients received pegylated interferon, 69 patients received classical interferon+ribavirin, 297 patients received pegylated-interferon+ribavirin, and three patients received classical interferon+ ribavirin+pegylated-interferon. Of the patients, 12 resulted in “exacerbation under treatment,” 14 with “partial response,” 89 with “relapse,” 124 with “no response,” and 179 with “sustained virologic response (SVR).” Overall, the most successful results were obtained in patients treated with pegylated interferon+ribavirin. In univariate comparisons, younger age, absence of splenomegaly, and absence of cirrhosis were significant in patients with SVR. In multivariate analysis, combined therapy was found to be independently significantly successful among patients with SVR. Discussion and Conclusion: In our study, the response rate of patients to interferon-based treatment was 42.8%, while young age, female gender, and absence of organomegaly were determined as factors that increased this rate, and according to multiple analyses, it was determined that combined treatment alone was effective on SVR independently.

🔖

Bu Makaleye Atıf Yap

VAHABOĞLU, M. H., KARADAĞ, F. Y., TUNCER, İ., ERGEN, P., ENÇ, F. Y., ULAŞOĞLU, C., AYDIN, Ö., DOĞRU, A., ÜÇIŞIK, A. C., YAZICI, S., EKİNCİ, S. Ç., KIZILTAŞ, Ş., GÜMÜŞER, F., TAŞAN, G., ÖZGÜNEŞ, N. (2022). The Success Rate of Interferon-Based Treatments in Chronic Viral Hepatitis C Patients and Factors Affecting Treatment Success. Haydarpaşa Numune Medical Journal, Cilt: 62 - Sayı: 1, 48–53. https://ajindex.com/articles/535861

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (11)

  1. WHO. Hepatit C. Available at: https://www.who.int/newsroom/ fact-sheets/detail/hepatitis-c. Accessed Jan 8, 2020
  2. Bukh J. The history of hepatitis C virus (HCV): Basic research reveals unique features in phylogeny, evolution and the viral life cycle with new perspectives for epidemic control. J Hepatol 2016;65:S2–S21
  3. Swain MG, Lai MY, Shiffman ML, Cooksley WG, Zeuzem S, Dieterich DT, et al. A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Gastroenterology 2010;139:1593–601
  4. Zeuzem S, Hultcrantz R, Bourliere M, Goeser T, Marcellin P, Sanchez-Tapias J. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004;40:993–9
  5. El-Zayadi AR, Attia M, Barakat EM, Badran HM, Hamdy H, El- Tawil A, et al. Response of hepatitis C genotype-4 naïve patients to 24 weeks of Peg-interferon-alpha2b/ribavirin or induction-dose interferon-alpha2b/ribavirin/amantadine: A non-randomized controlled study. Am J Gastroenterol 2005;100:2447–52
  6. Russo MW. Antiviral therapy for hepatitis C is associated with improved clinical outcomes in patients with advanced fibrosis. Expert Rev Gastroenterol Hepatol 2010;4:535–9
  7. Morgan TR, Ghany MG, Kim HY, Snow KK, Shiffman ML, De Santo JL, et al. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology 2010;52:833–44
  8. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346–55
  9. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 2001;358:958–65
  10. Kamal SM, El Tawil AA, Nakano T, He Q, Rasenack J, Hakam SA, et al. Peginterferon {alpha}-2b and ribavirin therapy in chronic hepatitis C genotype 4: Impact of treatment duration and viral kinetics on sustained virological response. Gut 2005;54:858–66
  11. Legrand-Abravanel F, Sandres-Sauné K, Barange K, Alric L, Moreau J, Desmorat P, et al. Hepatitis C virus genotype 5: Epidemiological characteristics and sensitivity to combination therapy with interferon-alpha plus ribavirin. J Inf